Sitemap | Contact Us  

Welcome To Taj Pharmaceuticals Ltd API      

About Worldwide  |     FAQs    |    Careers     | |        Media Center  |  |    Taj Pharmaceuticals  World   | |     TAJ Group 


       2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved

Pharma industries Taj API

      India              Latin America/ Caribbean            Africa & Middle East              Asia              Russia              Europe  
Pamidronate Disodium Manufacturers in India Suppliers Pamidronate Disodium Dossage Exporters Distributors Pamidronate Disodium api active pharmaceuticals ingredients Pamidronate Disodium manufacturers Side Effects bulk drugs raw material Dossage Pamidronate Disodium companies Side Effects Dossage Importers Pamidronate Disodium Dossage Pamidronate Disodium Exporters Pamidronate Disodium exporters Dossage FDA Dossage Pamidronate Disodium Dossage DMF Symptoms Dossage Generic Taj Pharmaceuticals Ltd. active pharmaceutical ingredients suppliers pharmaceutical Pamidronate Disodium manufacturing pharmaceutical drugs pharmaceutical intermediates Pamidronate Disodium pharmaceutical chemicals pharmaceutical raw materials Pamidronate Disodium active pharmaceutical ingredients Pamidronate Disodium committee active pharmaceutical ingredients manufacturer Pamidronate Disodium Active Pharmaceutical Ingredients manufacturer Pamidronate Disodium exporter drug ingredients pharmaceuticals Pharmaceuticals API Manufacturer Pamidronate Disodium, Pamidronate Disodium manufacturer India, Pamidronate Disodium product, Pamidronate Disodium products, Api preparation, Certificate of Analysis API manufacturer product, Pamidronate Disodium anti ulcer product, Certificate of Origin COA Pamidronate Disodium COS Pamidronate Disodium, pharmaceutical generic, pharmaceutical drug, medical, Pamidronate Disodium pharma healthcare, pharma patents, contract MSDS manufacturing Trader Pamidronate Disodium pharma, generic pharma, HCL pharma MSDS pharmaceutical products, pharmaceutical formulations, generic import API, Pamidronate Disodium expectorant Pharmaceutical GMP Method of analysis formulations manufacturer, Pamidronate Disodium DMF drug master file pharmaceutical Anti Cancer active ingredient exporter from India, pharma Pamidronate Disodium ingredients, api, HIV Pamidronate Disodium, tablets, capsules, syrup & protein Pamidronate Disodium powder, GMP of Plant api nutraceuticals, gynec products, ortho ingredients in India, oncology products, Pamidronate Disodium gastroenterology products, buy, sell orthopaedic product, who gmp, cGMP, US FDA, Pamidronate Disodium WHO, UKMHRA Approval
   PRODUCT LIST
   Home
   API >>>
   Pharmaceuticals API List
   Chemicals
   Manufacturing
   Product Development
   Product Search
   Agro Chemicals
   Custom Pharma Services
   Contact Us
 

pharmaceuticals




















































 

HOME >> API >> API List 3 >> Pamidronate Disodium >> Dosage

Disodium pamidronate CAS Number 109552-15-0

DOSAGE

Pamidronate Disodium  CAS Number 109552-15-0

Paget's Disease

Pamidronate Disodium is indicated for the treatment of patients with moderate to severe Paget's disease of bone. The effectiveness of Pamidronate Disodium was demonstrated primarily in patients with serum alkaline phosphatase ≥ 3 times the upper limit of normal. Pamidronate Disodium therapy in patients with Paget's disease has been effective in reducing serum alkaline phosphatase and urinary hydroxyproline levels by ≥ 50% in at least 50% of patients, and by ≥ 30% in at least 80% of patients. Pamidronate Disodium therapy has also been effective in reducing these biochemical markers in patients with Paget's disease who failed to respond, or no longer responded to other treatments.
Osteolytic Bone Metastases of Breast Cancer and Osteolytic Lesions of Multiple Myeloma

Pamidronate Disodium is indicated, in conjunction with standard antineoplastic therapy, for the treatment of osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma. The Pamidronate Disodium treatment effect appeared to be smaller in the study of breast cancer patients receiving hormonal therapy than in the study of those receiving chemotherapy, however, overall evidence of clinical benefit has been demonstrated.

Paget Disease

Adults

IV 30 mg/day as a 4-h infusion on 3 consecutive days for a total dose of 90 mg. For retreatment, same as initial therapy, when clinically indicated.
Osteolytic Bone Metastases of Breast Cancer

Adults

IV 90 mg as a 2-h infusion every 3 to 4 wk.
Osteolytic Bone Lesions of Multiple Myeloma
Adults

IV 90 mg as a 4-h infusion on a monthly basis. General Advice

* For IV administration only. Not for intradermal, subcutaneous, IM, intra-arterial, or oral administration.
* Concentrated injection solution must be further diluted before administration.
* Reconstitute lyophilized powder with 10 mL sterile water for injection. Allow drug to dissolve completely before withdrawing for further dilution.
* Do not administer if particulate matter or discoloration noted.
* Administer diluted solution via separate IV line.

Hypercalcemia of malignancy

* Dilute the recommended dose in 1,000 mL 0.45% or sodium chloride 0.9% or dextrose 5% injection. Infuse prescribed dose over 2 to 24 h as ordered.

Paget disease

* Dilute the recommended dose in 500 mL 0.45% or sodium chloride 0.9% or dextrose 5% injection. Infuse prescribed dose over 4 h.

Osteolytic bone lesions of multiple myeloma

* Dilute the recommended dose in 500 mL 0.45% or sodium chloride 0.9% or dextrose 5% injection. Infuse prescribed dose over 4 h.

Osteolytic bone metastases of breast cancer

* Dilute the recommended dose in 500 mL 0.45% or sodium chloride 0.9% or dextrose 5% injection. Infuse prescribed dose over 2 h.

Information Associated with Product:
DRUG DESCRIPTION
DOSAGE >>
SIDE EFFECTS
PRECAUTIONS
INTERACTION
CONSUMER INFORMATION
 
 
PDF DOWNLOAD WORD DOCUMENT
Product Enquiry Product Quotation Sample Request Place Your Order  
Product Enquiry Product Quotation Sample Request Place Your Order  

Taj Pharmaceuticals API Logo

Pamidronate Disodium

Copyright Taj Pharmaceuticals Ltd. | Privacy Policy | Terms & Conditions | Sitemap

Investor Relations    Feedback     Contact Worldwide    Sitemap

 

taj group logo
2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals Limited  products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals Ltd product or are experiencing a medical emergency, please consult your health care provider.
Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible.